Skip to Main Content
Table 1—

Patient characteristics at screening

OrlistatPlacebo
n 153 156 
Women 77 (50.3) 80 (51.3) 
Age (years) 47.2 (20–64) 46.7 (19–63) 
Weight (kg) 110 (75–162) 112 (78–152) 
BMI (kg/m²) 37.4 (30.1–45.2) 37.6 (30.0–45.0) 
Waist (cm) 119 (92–168) 119 (92–144) 
Impaired fastin glucose 38 (24.8) 45 (28.8) 
Diabetes 38 (24.8) 31 (19.9) 
Low HDL 69 (45.1) 65 (41.6) 
High triglycerides 91 (59.5) 92 (50.9) 
OrlistatPlacebo
n 153 156 
Women 77 (50.3) 80 (51.3) 
Age (years) 47.2 (20–64) 46.7 (19–63) 
Weight (kg) 110 (75–162) 112 (78–152) 
BMI (kg/m²) 37.4 (30.1–45.2) 37.6 (30.0–45.0) 
Waist (cm) 119 (92–168) 119 (92–144) 
Impaired fastin glucose 38 (24.8) 45 (28.8) 
Diabetes 38 (24.8) 31 (19.9) 
Low HDL 69 (45.1) 65 (41.6) 
High triglycerides 91 (59.5) 92 (50.9) 

Data are n (%) or mean (range). There were no significant differences between the two groups. Low HDL cholesterol ≤0.9/1.1 (mmol/l). High triglycerides >2.0 mmol/l.

Close Modal

or Create an Account

Close Modal
Close Modal